Ear Nose Throat Disorders

Sensorion’s SENS-401 meets secondary endpoints in Phase IIa hearing trial

France-based Sensorion has announced that its hearing loss candidate SENS-401 has a protective effect on early residual hearing loss after…

Sensorion unveils promising initial results from trial of SENS-401

Sensorion has unveiled promising preliminary results from its Proof of Concept (POC) Phase IIa trial of SENS-401 (Arazasetron) for the…

Altamira’s Bentrio nasal spray trial meets primary efficacy endpoint

Altamira Therapeutics has reported that the NASAR clinical trial of Bentrio nasal spray for seasonal allergic rhinitis (SAR) has met…

Lyra restarts second pivotal Phase III trial of LYR-210 nasal implant

Lyra Therapeutics has restarted screening and enrolment of patients in its second pivotal Phase III clinical trial, ENLIGHTEN II, of…

MHRA authorises Decibel’s CTA for trial of DB-OTO in paediatric patients

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has authorised Decibel Therapeutics’ clinical trial application (CTA) for initiating a…

Sensorion reports first patient enrolment in Phase IIa ototoxicity trial

Sensorion has reported the enrolment of the first patient in its Phase IIa proof of concept clinical trial of SENS-401…

Lyra Therapeutics enrols first subject in Phase III CRS therapy trial

Lyra Therapeutics has enrolled the first subject in the Phase III ENLIGHTEN II clinical trial to evaluate its investigational product…

DCT Adoption Tracker reveals top therapy areas using a decentralisation approach

Telemedicine remains the leading decentralisation approach in clinical trials in Q2 of this year. The continued rise of telemedicine as…

Sensorion’s sudden sensorineural hearing loss asset fails Phase II test

Sensorion announced that the Phase II AUDIBLE-S clinical trial of its drug candidate SENS-401 (Arazasetron) to treat sudden sensorineural hearing…

Frequency’s Phase IIa hearing loss trial shows no benefit versus placebo

Day-90 data from a Phase IIa study of four dosing regimens of Frequency Therapeutics’ hearing loss treatment FX-322 in subjects…

close

Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Vist our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close